Local physiological changes during photodynamic therapy

Lasers in Surgery and Medicine

Volumn 38, Issue 5, 2006, Pages 494-499

  Busch, Theresa M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Blood flow; EF3; EF5; Hypoxia; Oxygen; pO2; SO2; Tumor

Indexed keywords

2 (2 NITROIMIDAZOL 1 YL) N (3,3,3 TRIFLUOROPROPYL)ACETAMIDE; ACETAMIDE DERIVATIVE; OXYGEN; OXYHEMOGLOBIN; PHOTOFRIN; PHOTOSENSITIZING AGENT; UNCLASSIFIED DRUG;

ARTICLE; DIFFUSE REFLECTANCE SPECTROSCOPY; FIBROSARCOMA; HEMODYNAMICS; HYPOXIA; NONHUMAN; OXYGEN CONSUMPTION; OXYGEN TISSUE LEVEL; OXYGENATION; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; TUMOR BLOOD FLOW;

ANIMALS; ANOXIA; NEOPLASMS; OXYGEN CONSUMPTION; PHOTOCHEMOTHERAPY; REACTIVE OXYGEN SPECIES; REGIONAL BLOOD FLOW;

EID: 33745685637     PISSN: 01968092     EISSN: 10969101     Source Type: Journal    
DOI: 10.1002/lsm.20355     Document Type: Article

References (41)

1. Henderson BW, Waldow SM, Mang TS, Potter WR, Malone PB, Dougherty TJ. Tumor destruction and kinetics of tumor cell death in two experimental mouse tumors following photodynamic therapy. Cancer Res 1985;45(2):572-576.
2. Tromberg BJ, Orenstein A, Kimel S, Barker SJ, Hyatt J, Nelson JS, Berns MW. In vivo tumor oxygen tension measurements for the evaluation of the efficiency of photodynamic therapy. Photochem Photobiol 1990;52(2):375-385.
3. Foster TH, Murant RS, Bryant RG, Knox RS, Gibson SL, Hilf R. Oxygen consumption and diffusion effects in photodynamic therapy. Radiat Res 1991;126(3):296-303.
4. Henning JP, Fournier RL, Hampton JA. A transient mathematical model of oxygen depletion during photodynamic therapy. Radiat Res 1995;142(2):221-226.
5. Foster TH, Hartley DF, Nichols MG, Hilf R. Fluence rate effects in photodynamic therapy of multicell tumor spheroids. Cancer Res 1993;53(6):1249-1254.
6. Sitnik TM, Hampton JA, Henderson BW. Reduction of tumour oxygenation during and after photodynamic therapy in vivo: Effects effluence rate. Br J Cancer 1998;77(9):1386-1394.
7. Coutier S, Bezdetnaya LN, Foster TH, Parache RM, Guillemin F. Effect of irradiation fluence rate on the efficacy of photodynamic therapy and tumor oxygenation in meta-tetra (hydroxyphenyl) chlorin (mTHPC)-sensitized HT29 xenografts in nude mice. Radiat Res 2002;158(3):339-345.
8. Busch TM, Hahn SM, Evans SM, Koch CJ. Depletion of tumor oxygenation during photodynamic therapy: Detection by the hypoxia marker EF3 [2-(2-nitroimidazol-1[H]-yl)-N-(3,3,3,-trifluoropropyl)acetamide]. Cancer Res 2000;60: 2636-2642.
9. Busch TM, Wileyto EP, Evans SM, Koch CJ. Quantitative spatial analysis of hypoxia and vascular perfusion in tumor sections. Adv Exp Med Biol 2003;510:37-43.
10. Busch TM, Wileyto EP, Emanuele MJ, Del Piero F, Marconato L, Glatstein E, Koch CJ. Photodynamic therapy creates fluence rate-dependent gradients in the intratumoral spatial distribution of oxygen. Cancer Res 2002;62(24):7273-7279.
11. Pogue BW, Braun RD, Lanzen JL, Erickson C, Dewhirst MW. Analysis of the heterogeneity of pO2 dynamics during photodynamic therapy with verteporfin. Photochera Photobiol 2001;74(5):700-706.
12. Wang HW, Putt ME, Emanuele MJ, Shin DB, Glatstein E, Yodh AG, Busch TM. Treatment-induced changes in tumor oxygenation predict photodynamic therapy outcome. Cancer Res 2004;64(20):7553-7561.
13. Gibson SL, VanDerMeid KR, Murant RS, Raubertas RF, Hilf R. Effects of various photoradiation regimens on the antitumor efficacy of photodynamic therapy for R3230AC mammary carcinomas. Cancer Res 1990;50(22):7236-7241.
14. Sitnik TM, Henderson BW. Effects of fluence rate on cytotoxicity during photodynamic therapy. Proceedings of SPIE. Volume 2972, Optical methods for tumor treatment and detection: Methods and techniques in photodynamic therapy VI: SPIE-The International Society for Optical Engineering; 1997. p 95-102.
15. Henderson BW, Sitnik-Busch TM, Vaughan LA. Potentiation of PDT anti-tumor activity in mice by nitric oxide synthase inhibition is fluence rate dependent. Photochem Photobiol 1999;70(1):64-71.
16. Sitnik TM, Henderson BW. The effect of fluence rate on tumor and normal tissue responses to photodynamic therapy. Photochem Photobiol 1998;67(4):462-466.
17. Iinuma S, Schomacker KT, Wagnieres G, Rajadhyaksha M, Bamberg M, Momma T, Hasan T. In vivo fluence rate and fractionation effects on tumor response and photobleaching: Photodynamic therapy with two photosensitizers in an orthotopic rat tumor model. Cancer Res 1999;59(24):6164-6170.
18. Muller S, Walt H, Dobler-Girdziunaite D, Fiedler D, Haller U. Enhanced photodynamic effects using fractionated laser light. J Photochem Photobiol B 1998;42(1):67-70.
19. Chen Q, Huang Z, Chen H, Shapiro H, Beckers J, Hetzel FW. Improvement of tumor response by manipulation of tumor oxygenation during photodynamic therapy. Photochem Photobiol 2002;76(2):197-203.
20. Huang Z, Chen Q, Shakil A, Chen H, Beckers J, Shapiro H, Hetzel FW. Hyperoxygenation enhances the tumor cell killing of photofrin-mediated photodynamic therapy. Photochem Photobiol 2003;78(5):496-502.
21. Maier A, Tomaselli F, Anegg U, Rehak P, Fell B, Luznik S, Pinter H, Smolle-Juttner FM. Combined photodynamic therapy and hyperbaric oxygenation in carcinoma of the esophagus and the esophago-gastric junction. Eur J Cardiothorac Surg 2000;18(6):649-654.
22. Pogue BW, O'Hara JA, Goodwin IA, Wilmot CJ, Fournier GP, Akay AE, Swartz H. Tumor PO(2) changes during photodynamic therapy depend upon photosensitizer type and time after injection. Comp Biochem Physiol A Mol Integr Physiol 2002;132(1):177-184.
23. Chen B, Pogue BW, Goodwin IA, O'Hara JA, Wilmot CJ, Hutchins JE, Hoopes PJ, Hasan T. Blood flow dynamics after photodynamic therapy with verteporfin in the RIF-1 tumor. Radiat Res 2003;160:452-459.
24. Pham TH, Hornung R, Berns MW, Tadir Y, Tromberg BJ. Monitoring tumor response during photodynamic therapy using near-infrared photon-migration spectroscopy. Photochem Photobiol 2001;73(6):669-677.
25. Woodhams JH, Kunz L, Bown SG, MacRobert AJ. Correlation of real-time haemoglobin oxygen saturation monitoring during photodynamic therapy with microvascular effects and tissue necrosis in normal rat liver. Br J Cancer 2004;91(4): 788-794.
26. Kostenich G, Kimel S, Peled S, Orenstein A. Monitoring PDT-induced damage using spectrally resolved reflectance imaging of tissue oxygenation. Cancer Lett 2005;219(2):169-175.
27. Niedre MJ, Yu CS, Patterson MS, Wilson BC. Singlet oxygen luminescence as an in vivo photodynamic therapy dose metric: Validation in normal mouse skin with topical amino-levulinic acid. Br J Cancer 2005;92(2):298-304.
28. Fingar VH, Wieman TJ, Wiehle SA, Cerrito PB. The role of microvascular damage in photodynamic therapy: The effect of treatment on vessel constriction, permeability, and leukocyte adhesion. Cancer Res 1992;52(18):4914-4921.
29. Yu G, Durduran T, Zhou C, Wang HW, Putt ME, Saunders HM, Sehgal CM, Glatstein E, Yodh AG, Busch TM. Noninvasive monitoring of murine tumor blood flow during and after photodynamic therapy provides early assessment of therapeutic efficacy. Clin Cancer Res 2005;11(9):3543-3552.
30. Fingar VH, Kik PK, Haydon PS, Cerrito PB, Tseng M, Abang E, Wieman TJ. Analysis of acute vascular damage after photodynamic therapy using benzoporphyrin derivative (BPD). Br J Cancer 1999;79(11-12):1702-1708.
31. McMahon KS, Wieman TJ, Moore PH, Fingar VH. Effects of photodynamic therapy using mono-L-aspartyl chlorin e6 on vessel constriction, vessel leakage, and tumor response. Cancer Res 1994;54(20):5374-5379.
32. Saito K, Mikuniya N, Aizawa K. Effects of photodynamic therapy using mono-L-aspartyl chlorin e6 on vessels and its contribution to the antitumor effect. Jpn J Cancer Res 2000; 91(5):560-565.
33. Chen B, Pogue BW, Hoopes PJ, Hasan T. Combining vascular and cellular targeting regimens enhances the efficacy of photodynamic therapy. Int J Radiat Oncol Biol Phys 2005; 61(4):1216-1226.
34. Kurohane K, Tominaga A, Sato K, North JR, Namba Y, Oku N. Photodynamic therapy targeted to tumor-induced angiogenic vessels. Cancer Lett 2001;167(1):49-56.
35. Busch TM, Hahn SM, Wileyto EP, Koch CJ, Fraker DL, Zhang P, Putt M, Gleason K, Shin DB, Emanuele MJ, Jenkins K, Glatstein E, Evans SM. Hypoxia and Photofrin uptake in the intraperitoneal carcinomatosis and sarcomatosis of photodynamic therapy patients. Clin Cancer Res 2004;10(14):4630-4638.
36. Menon C, Kutney SN, Lehr SC, Hendren SK, Busch TM, Hahn SM, Fraker DL. Vascularity and uptake of photosensitizer in small human tumor nodules: Implications for intraperitoneal photodynamic therapy. Clin Cancer Res 2001;7(12):3904-3911.
37. Wang HW, Zhu TC, Putt ME, Solonenko M, Metz J, Dimofte A, Miles J, Fraker DL, Glatstein E, Hahn SM, Yodh AG. Broadband reflectance measurements of light penetration, blood oxygenation, hemoglobin concentration, and drug concentration in human intraperitoneal tissues before and after photodynamic therapy. J Biomed Opt 2005;10(1):14004.
38. Thompson MS, Johansson A, Johansson T, Andersson-Engels S, Svanberg S, Bendsoe N, Svanberg K. Clinical system for interstitial photodynamic therapy with combined on-line dosimetry measurements. Appl Opt 2005;44(19):4023-4031.
39. Yu G, Durduran T, Zhou C, Zhu T, Finlay JC, Busch TM, Malkowicz SB, Hahn SM, Yodh AG. Real-time in situ monitoring of human prostate photodynamic therapy with diffuse light. Photochem Photobiol 2005 (submitted).
40. Henderson BW, Busch TM, Vaughan LA, Frawley NP, Babich D, Sosa TA, Zollo JD, Dee AS, Cooper MT, Bellnier DA, Greco WR, Oseroff AR. Photofrin photodynamic therapy can significantly deplete or preserve oxygenation in human basal cell carcinomas during treatment, depending on fluence rate. Cancer Res 2000;60(3):525-529.
41. Ericson MB, Sandberg C, Stenquist B, Gudmundson F, Karlsson M, Ros AM, Rosen A, Larko O, Wennberg AM, Rosdahl I. Photodynamic therapy of actinic keratosis at varying fluence rates: Assessment of photobleaching, pain and primary clinical outcome. Br J Dermatol 2004;151(6): 1204-1212.